QQQ0.25%

Trending

SPCE26.71%

home Symbol ARWRnews

ARWR
Arrowhead Pharmaceuticals Inc.

12,372

Mkt Cap

$11.13B

Volume

510,137.00

52W High

$82.26

52W Low

$14.30

PE Ratio

-36.79

ARWR Fundamentals

Price

$77.49

Prev Close

$79.05

Open

$79.23

50D MA

$69.44

Beta

1.67

Avg. Volume

1.77M

EPS (Annual)

-$0.0122

P/B

18.10

Rev/Employee

$1.17M

$4,464.99

Info

News

all

press releases

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the companys investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis...

Business Wire

More News

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moderate-to-severe renal impairment or moderate hepatic impairment without the need for dose adjustment, and a case report suggesting that preconception...

Business Wire

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money Wall Street's Cardiac Bet: Where Diagnostics Meet the Money PR Newswire VANCOUVER, BC, May 12, 2026 ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News CommentaryVANCOUVER, BC, May 12, 2026 /PRNewswire/ --Cardiovascular...

PR Newswire

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026...

Business Wire

Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained

SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.

Zacks

Strs Ohio Has $2.09 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Strs Ohio grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 205.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities...

MarketBeat

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 12-Month High - Time to Buy?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High - Should You Buy...

MarketBeat

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowheads clinical stage RNA...

Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference May 12-14, 2026 Type...

Business Wire

Kornitzer Capital Management Inc. KS Makes New $2.38 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR

Kornitzer Capital Management Inc. KS bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to its most recent filing with...

MarketBeat

...